Mitochondrial iron routing through mitoferrin-1 as a determinant of ferroptotic vulnerability to clinically used iron formulations in ovarian cancer
This study identifies mitochondrial iron routing via mitoferrin-1 (MFRN1) as the critical determinant of ferroptotic vulnerability in ovarian cancer, demonstrating that clinically used parenteral iron formulations selectively kill sensitive tumor cells by inducing lethal mitochondrial iron overload and bioenergetic failure while sparing resistant cells and normal tissue.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Ovarian cancer remains one of the most dangerous diseases affecting women, largely because tumors often learn to ignore the standard chemotherapy drugs used to treat them. When these drugs fail, doctors need new ways to kill cancer cells that do not rely on the same biological pathways the tumor has already learned to bypass. One promising avenue involves a type of cell death called ferroptosis. Unlike the more familiar form of cell suicide, which involves a clean, programmed shutdown, ferroptosis is a messy, rust-like process. It happens when iron builds up inside a cell to dangerous levels, causing fats in the cell's membrane to go rancid and the cell to burst. Because ovarian cancer cells are known to hoard iron to fuel their rapid growth, scientists have long suspected they might be vulnerable to this specific kind of destruction. However, previous attempts to trigger this effect relied on experimental chemicals that are not safe or approved for use in people, leaving a gap between laboratory theory and real-world treatment.
A team of researchers set out to bridge this gap by testing whether iron formulations already approved for human use could trigger this lethal rusting effect in ovarian cancer. They worked with four different types of ovarian cancer cells found in patients, along with a type of healthy ovarian cell to serve as a control. The scientists treated these cells with three different iron-based medicines that are commonly given to patients to treat anemia: ferric gluconate, ferric ammonium citrate, and iron dextran. The results were striking and immediate. Two of the cancer cell lines, which the researchers named PEA1 and COV362, began to die rapidly when exposed to the iron. The healthy cells, however, remained unharmed. The researchers confirmed that the cancer cells were not dying from the usual causes, such as the cell's internal machinery shutting down or the cell simply falling apart. Instead, the cells were dying specifically from ferroptosis, a conclusion drawn because the death could be stopped only by a drug known to block ferroptosis, while drugs that block other forms of cell death had no effect.
The study then turned to a critical question: why did some cancer cells die while others, exposed to the exact same amount of iron, survived? The researchers discovered that the difference was not about how much iron the cells took in, but rather where that iron went once it was inside. The cells that survived had a sophisticated defense system. When they sensed an overload of iron, they immediately reduced the number of doors on their surface that let iron in, increased the number of pumps that pushed iron out, and built up storage containers to hold the excess safely. Furthermore, these resistant cells had a way to identify and destroy their own mitochondria—the tiny power plants inside the cell—whenever those power plants became damaged by the iron. This process of cleaning out the damaged parts allowed the resistant cells to keep functioning.
In contrast, the cells that died failed to activate these protective measures. Instead of keeping the iron in a safe storage area or pushing it out, they allowed the iron to flood directly into their mitochondria. This influx of iron caused a surge of harmful chemical activity inside the power plants, leading to a catastrophic failure of the cell's energy system and triggering the rust-like death. The researchers identified a specific protein, which acts like a gatekeeper for iron entering the mitochondria, as the key factor in this process. When they used a technique to silence this gatekeeper in the sensitive cells, the cells suddenly became resistant to the iron treatment. The iron still entered the cell, but it could no longer reach the mitochondria, and the cells survived. This proved that the lethal factor was not the total amount of iron in the cell, but specifically the iron that managed to reach the mitochondria.
To see if these findings held true in a living system, the researchers grew tumors from the sensitive and resistant cells in mice. They then treated the mice with iron dextran, the same iron formulation used in the lab dishes. The treatment caused the sensitive tumors to shrink significantly, reducing their volume by about two-thirds, while the resistant tumors continued to grow as if nothing had happened. The researchers examined the tumors after treatment and found clear signs of ferroptosis in the shrinking ones, including a drop in the cell's natural antioxidant defenses and an increase in markers of iron-induced damage. Crucially, the treatment did not cause the mice to become sick or lose weight, and it did not trigger the standard cell-death pathways that chemotherapy usually relies on.
This work suggests that the vulnerability of ovarian cancer to iron-based treatments is determined by a specific internal routing system. If a tumor cell allows iron to travel into its mitochondria, it will die; if it can successfully block that path and clean up the damage, it will survive. The study demonstrates that iron formulations already available in clinics could be repurposed to target a specific subset of ovarian cancer patients whose tumors lack this protective routing mechanism. By focusing on how the cell handles iron rather than just how much it takes in, the researchers have identified a new way to distinguish between tumors that can be killed by this approach and those that cannot, offering a potential new strategy for patients who have run out of other treatment options.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.